CHM-2101 CAR-T cell for GI Cancers
A Phase 1 / 2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
IDENTIFIER (ClinicalTrials.gov): NCT06055439
DRUG/TREATMENT: CHM-2101 CAR-T Cells
PHASE: 1/2
STATUS: Recruiting
SPONSOR: Chimeric Therapeutics
DESCRIPTION:
Chimeric Therapeutics is sponsoring a Phase 1/2 open-label study to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced G1, G2, and well-differentiated G3 neuroendocrine tumors of the midgut and hindgut (ileal, jejunal, cecal, distal colonic, or rectal; with ≤ 55% Ki67 expression) that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.
Phase 1 involves dose escalation and expansion. The recommended Phase 2 dose will be based on results from the Phase 1.
For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.
CONTACT:Â
Jason B. Litten, MD
EMAIL: jlitten@chimerictherapeutics.com
PHONE: 415-802-4360
RELATED RESOURCES